33 related articles for article (PubMed ID: 16408192)
1. Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1.
Tucker T; Riccardi VM; Sutcliffe M; Vielkind J; Wechsler J; Wolkenstein P; Friedman JM
J Histochem Cytochem; 2011 Jun; 59(6):584-90. PubMed ID: 21525187
[TBL] [Abstract][Full Text] [Related]
2. Secretome survey of human plexiform neurofibroma derived Schwann Cells reveals a secreted form of the RARRES1 protein.
Chen HL; Seol H; Brown KJ; Gordish-Dressman H; Hill A; Gallo V; Packer R; Hathout Y
Int J Mol Sci; 2012; 13(7):9380-9399. PubMed ID: 22942771
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
5. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
[TBL] [Abstract][Full Text] [Related]
6. Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum.
Kliem H; Welter H; Kraetzl WD; Steffl M; Meyer HH; Schams D; Berisha B
Reproduction; 2007 Sep; 134(3):535-47. PubMed ID: 17709571
[TBL] [Abstract][Full Text] [Related]
7. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Sirén V; Peltonen J; Vaheri A
Arch Dermatol Res; 2006 Mar; 297(9):421-4. PubMed ID: 16408192
[TBL] [Abstract][Full Text] [Related]
9. Post-transcriptional regulation of gene expression in the plasminogen activation system.
Montuori N; Rossi G; Ragno P
Biol Chem; 2002 Jan; 383(1):47-53. PubMed ID: 11928821
[TBL] [Abstract][Full Text] [Related]
10. The plasminogen activator inhibitor "paradox" in cancer.
Binder BR; Mihaly J
Immunol Lett; 2008 Jun; 118(2):116-24. PubMed ID: 18495253
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional and posttranscriptional regulation of the plasminogen activator system.
Nagamine Y; Medcalf RL; Muñoz-Cánoves P
Thromb Haemost; 2005 Apr; 93(4):661-75. PubMed ID: 15841310
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between plasminogen activator, plasminogen activator inhibitor and Sertoli cells].
Wang XY; Xiong CL
Zhonghua Nan Ke Xue; 2003 Apr; 9(2):133-5, 139. PubMed ID: 12749136
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
